TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. a joint pediatric blood and marrow transplant consortium and children's oncology group study (ASCT0521)

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 67-73

  Yanik, Gregory A ^a   Grupp, Stephan A ^b   Pulsipher, Michael A ^c   Levine, John E ^a   Schultz, Kirk R ^d   Wall, Donna A ^e   Langholz, Bryan ^f   Dvorak, Christopher C ^g   Alangaden, Keith ^a   Goyal, Rakesh K ^h   White, Eric S ^a   Collura, Jennifer M ⁱ   Skeens, Micah A ^j   Eid, Saada ^k   Pierce, Elizabeth M ^k   Cooke, Kenneth R ^l  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^d BC CHILDREN S HOSPITAL   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j NATIONWIDE CHILDREN S HOSPITAL   (United States)

^k CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Bone marrow transplantation; Etanercept; Idiopathic pneumonia syndrome

Indexed keywords

ANGIOPOIETIN 2; CORTICOSTEROID; ETANERCEPT; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE BINDING PROTEIN; OXYGEN; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IDIOPATHIC PNEUMONIA SYNDROME; LUNG LAVAGE; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RADIOGRAPHY; SURVIVAL; TREATMENT RESPONSE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CYTOLOGY; HEMATOLOGIC NEOPLASMS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IMMUNOLOGY; INFANT; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SIBLING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNRELATED DONORS;

ADOLESCENT; ADRENAL CORTEX HORMONES; BRONCHOALVEOLAR LAVAGE FLUID; CHILD; CHILD, PRESCHOOL; CYTOKINES; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RESPIRATION, ARTIFICIAL; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84927144497     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.09.019     Document Type: Article

References (35)

1. Kantrow S.P., Hackman R.C., Boeckh M., et al. Idiopathic pneumonia syndrome: Changing spectrum of lung injury after marrow transplantation. Transplantation 1997, 63:1079-1086.
2. Crawford S.W., Hackman R.C. Clinical course of idiopathic pneumonia after bone marrow transplantation. Am Rev Respir Dis 1993, 147:1393-1400.
3. Yanik G., Hellerstedt B., Custer J., et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:395-400.
4. Clark J.G., Hansen J.A., Hertz M.I., et al. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993, 147:1601-1606.
5. Panoskaltsis-Mortari A., Griese M., Madtes D.K., et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med 2011, 183:1262-1279.
6. Yanik G.A., Ho V.T., Levine J.E., et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008, 112:3073-3081.
7. Fukuda T., Hackman R.C., Guthrie K.A., et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003, 102:2777-2785.
8. Yanik G.A., Horowitz M.M., Weisdorf D.J., et al. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant 2014, 20:858-864.
9. Sakaguchi H., Takahashi Y., Watanabe N., et al. Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in children. Pediatr Blood Cancer 2012, 58:780-784.
10. Sano H., Kobayashi R., Iguchi A., et al. Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children. Bone Marrow Transplant 2014, 49:38-41.
11. Versluys A.B., Rossen J.W., van Ewijk B., et al. Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes. Biol Blood Marrow Transplant 2010, 16:782-791.
12. Clark J.G., Madtes D.K., Martin T.R., et al. Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment. Crit Care Med 1999, 27:1800-1806.
13. Cooke K.R., Hill G.R., Gerbitz A., et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000, 70:272-279.
14. Cooke K.R., Hill G.R., Gerbitz A., et al. Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation. JImmunol 2000, 165:6612-6619.
15. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996, 88:3230-3239.
16. Hildebrandt G.C., Olkiewicz K.M., Corrion L.A., et al. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004, 104:586-593.
17. Panoskaltsis-Mortari A., Taylor P.A., Yaegar T.M., et al. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogenic recipients are due to donor T cell infusion and potentiated by cyclophoshamide. JClin Invest 1997, 100:1015-1027.
18. Clark J.G., Madtes D.K., Hackman R.C., et al. Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages. JImmunol 1998, 161:1913-1920.
19. Hildebrandt G.C., Duffner U.A., Olkiewicz K.M., et al. Acritical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004, 103:2417-2426.
20. Tizon R., Frey N., Heitjan D.F., et al. High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant 2012, 47:1332-1337.
21. Keates-Baleeiro J., Moore P., Koyama T., et al. Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients. Bone Marrow Transplant 2006, 38:285-289.
22. Chen Z., Ji J., Li M., et al. [Detection of serum Th1 and Th2 cytokines and its significance in neonates with cytomegalovirus pneumonia]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007, 21:361-363.
23. Mohty M., Blaise D., Faucher C., et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005, 106:4407-4411.
24. Brownback K.R., Simpson S.Q., McGuirk J.P., et al. Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation. Ann Hematol 2014, 93:847-854.
25. Kanda J., Kaynar L., Kanda Y., et al. Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. Bone Marrow Transplant 2013, 48:926-931.
26. Frangoul H., Wang L., Harrell F.E., et al. Preengraftment syndrome after unrelated cord blood transplant is a strong predictor of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:1485-1488.
27. Cooke K.R., Jannin A., Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:23-32.
28. Gerbitz A., Nickoloff B.J., Olkiewicz K., et al. Arole for tumor necrosis factor-alpha-mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome. Transplantation 2004, 78:494-502.
29. Luft T., Dietrich S., Falk C., et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011, 118:1685-1692.
30. Gallagher D.C., Parikh S.M., Balonov K., et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008, 29:656-661.
31. Parikh S.M., Mammoto T., Schultz A., et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006, 3:e46.
32. van der Heijden M., van Nieuw Amerongen G.P., Koolwijk P., et al. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008, 63:903-909.
33. Schlatzer D.M., Dazard J.E., Ewing R.M., et al. Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Mol Cell Proteomics 2012, 11. M111.015479.
34. Reshef R., Luger S.M., Hexner E.O., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. NEngl J Med 2012, 367:135-145.
35. Wee S., Pascual M., Eason J., et al. Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant patients who receive OKT3 therapy. Transplantation 1997, 63:570-577.